Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.

ABSTRACT:

Objective

This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS).

Methods

We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results.

Results

Of 844 PwMS wi

SUBMITTER: Sormani MP 

PROVIDER: S-EPMC8013440 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature